Louisiana HB761 revises the advisory board for rare cancer treatments, increasing the number of oncologists and changing reporting deadlines.

Louisiana HB761 amends the composition of the advisory board for rare cancer treatments, increasing the number of oncologists specializing in rare cancers. The board, within the Department of Insurance, reviews and provides medical recommendations for new treatments. The chairperson remains the executive director or designee of the Louisiana Cancer Research Center. The board holds quarterly public meetings and must submit written reports to the legislature within forty-five days of each meeting.

Louisiana HB761 revises the advisory board for rare cancer treatments, increasing the number of oncologists and changing reporting deadlines.

Louisiana HB761 amends the composition of the advisory board for rare cancer treatments, increasing the number of oncologists specializing in rare cancers. The board, within the Department of Insurance, reviews and provides medical recommendations for new treatments. The chairperson remains the executive director or designee of the Louisiana Cancer Research Center. The board holds quarterly public meetings and must submit written reports to the legislature within forty-five days of each meeting.